Longboard Pharmaceuticals Revenue
Biotechnology Research • 
San Diego, California, United States • 21-50 Employees
Longboard Pharmaceuticals revenue & valuation
| Annual revenue | $2,481,095 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $8,000,000 |
| Total funding | $23,000,000 |
Key Contacts at Longboard Pharmaceuticals
Sophia Cacciatore
Director, Patient Advocacy
Marc Nelson
Senior Director, Project Management Office
Sunil Gali Pmp
Senior Director Clinical Qa & Compliance
Kenneth B. Mackay
Senior Director, Toxicology
Scott Hofsess
Senior Director And Head Of Vendor Management
Rosa Chan
Director
Shakti Valdez
Director, Regulatory Affairs
Phillip Schneider
Director And Audit Committee Chair
Rachel Graves
Senior Director, Cmc
Sandhya Rege
Associate Director, Nonclinical Project Management
Company overview
| Headquarters | 4275 Executive Square, Suite 950, La Jolla, CA 92037, US |
| Phone number | +18587899283 |
| Website | |
| NAICS | 541714 |
| Founded | 2020 |
| Employees | 21-50 |
| Socials |
Longboard Pharmaceuticals Email Formats
Longboard Pharmaceuticals uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@longboardpharma.com), used 76.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@longboardpharma.com | 76.2% |
{first name}{last name} | johndoe@longboardpharma.com | 23.8% |
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. Longboard recently reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants ages 12 to 65 years old with Developmental and Epileptic Encephalopathies (DEEs), including Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Longboard Pharmaceuticals has 18 employees across 6 departments.
Departments
Number of employees
Longboard Pharmaceuticals Tech Stack
Discover the technologies and tools that power Longboard Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
Video players
JavaScript libraries
JavaScript libraries
CDN
Font scripts
WordPress themes
JavaScript libraries
Webmail
Miscellaneous
United Arab Emirates
Belgium
South Africa
Korea, Republic ofFrequently asked questions
4.8
40,000 users
